Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: J&J, Jenavalve, Mammotmoe, Myriad, Peijia, Roche, Sanofi, Spinal Elements.

Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Aldeyra, Biocardia, Fujirebio, Gyre, H.U. Group, Humacyte, Oxos, Perfuze, Polaryx, Polypid.

Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Argo, Astrazeneca, Cogent, Glafabra, Koru Medical, Novartis, Roche, Sun, Telix.

Regulatory snapshots for biopharma and med tech in Asia-Pacific, including global submissions and approvals, and other regulatory decisions and designations: Astrazeneca, Daiichi Sankyo, Junshi, Nanosonics, Ultragreen.ai.

Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Aminex, GSK, Mineralys.

Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Atara, Johnson & Johnson, Pierre, Toro, Ultragreen, Xspray.

Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Arthex, Cairn, Cellavision, Memed, Minimed, Parabilis, Qiagen, Quoin, Tolerogenixx.

Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Biocartis, Capricor, Centauri, Eledon, Genfit, Incyte, Johnson & Johnson, Lenz, Mineralys, QT Imaging, Soligenix.

Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Astrazeneca, BMS, Chiesi, Claritas, Daiichi, Immunitybio, Incyte, Johnson & Johnson, Junshi, MBX, Nanosonics, PMV, Precision, Protalix, Sangamo, Savara.

Regulatory snapshots for biopharma and med tech in Asia-Pacific, including global submissions and approvals, and other regulatory decisions and designations: Accord, Asieris, Claritas, Drug Farm, Foresee, Glenmark, Nxera, Hua Medicine, Innocare, Innovent, Meiji, Pepgen, Pharmaessentia, Protagonist, Sanofi, Sciwind, Sumitomo, Takeda.